Introduction
The efficacy of treating Pseudomonas aeruginosa lung infection in cystic fibrosis patients has been debated. 1 Data from Denmark 2 offer strong arguments in favour, and Regelmann et al. 3 have shown that antibiotics are more efficacious for the treatment of P. aeruginosa lung infection when compared with bronchodilators and chest physiotherapy alone. However, the optimal drug or treatment schedule is not known. We previously compared piperacillin-tobramycin with ceftazidime monotherapy and found no significant difference. 4 Once chronic infection with P. aeruginosa has commenced, the bacteria are seldom eradicated by antibiotic therapy. The use of high-dose intravenous therapy to keep endobronchial antibiotic levels above the MIC for P. aeruginosa might be necessary to eradicate this bacterium from the lungs of those with cystic fibrosis. 5 The present study assessed whether a high dose of ceftazidime would be safe, more effective in improving pulmonary function and chest radiographs, and produce a longer-lasting clinical improvement than a conventional dose.
Materials and methods
All patients with cystic fibrosis (CF) admitted to hospital because of signs of increasing lung infection were enrolled in the study provided they were chronically colonized (at least 6 months) with P. aeruginosa sensitive to ceftazidime (MIC 8 mg/L as determined by agar disc diffusion method). The decision to admit patients for intravenous therapy was based on at least two of the following parameters: clinical deterioration (manifested by at least three of the following criteria: increased cough and sputum production, fatigue, poor appetite and weight loss) not improving after 5-7 days of intensification of physiotherapy at home, deteriorating pulmonary function test (20% decrease in forced expired volume in 1 s (FEV1)) or a new consolidation on chest X-ray. Patients colonized with Burkholderia cepacia or non-typable Pseudomonas spp. were excluded. The study was approved by the hospital's Ethics Committee and the patients gave fully informed written consent. Patients were randomized on admission to receive ceftazidime 150 mg/kg/day or 320 mg/kg/day in four doses for 14 days. Each infusion was administered over 20 min. Patients were unaware of the dosage used. Treatment also consisted of a hypercaloric diet with pancreatic enzyme replacement and vitamin supplements as well as aerosol inhalations with mesna and chest physiotherapy twice a day. Bronchodilators (0.5 mL of salbutamol, 0.5% w/v) were added to the aerosol therapy in patients who manifested a 10% improvement in FEV1.
All patients were weighed on admission and at discharge. Blood analysis included erythrocyte sedimentation rate (ESR), WBC and differential, platelet count, serum alanine aminotransferase (ALT) and serum creatinine. On days 1 and 14, pulmonary function was measured in a pressure body plethysmograph (Jaeger, GmbH, Würzburg, Germany) by a technician unaware of the
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Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis
with high or conventional doses of ceftazidime In cystic fibrosis patients with Pseudomonas aeruginosa colonization and increasing pulmonary infection, ceftazidime 150 mg/kg/day was compared with 320 mg/kg/day. Changes in clinical findings, laboratory tests, pulmonary function and chest radiographs were evaluated after 14 days of treatment in hospital. Both treatments were associated with a significant improvement, but the higher dose did not offer an additional benefit. An increase in alanine aminotransferase (ALT) occurred after both treatments; with a significantly greater increase after the high-dose therapy (mean increase ± S.E.M. 8% ± 2% vs 2% ± 1%; P < 0.01). All but one of the ALT values after treatment were within normal limits. 6 Standard anteroposterior and lateral chest X-rays were scored according to the method of Brasfield & Hicks.
7 Sputum samples were grown on MacConkey agar and plated heavily on one third of the agar, in streaks over the next third of the agar and lightly on the remaining third. In a semiquantitative assessment, growth was standardized as follows: 0, fewer than ten colonies; , more than ten colonies but growth only on the first (heavily plated) third of the agar;
, growth on the first and second thirds of the agar;
, growth on the whole plate. Statistical analysis was by a paired or unpaired t-test when the values were normally distributed, and the MannWhitney test or contingency table otherwise. P values of 0.05 were considered statistically significant.
Results
Thirty-three treatments were randomized to 17 courses of high-dose ceftazidime and 16 courses of conventional dose ceftazidime. Age, sex, height, weight, duration of P. aeruginosa colonization and pulmonary function tests at entry to the study were similar in both groups (Tables I  and II) . The patients' weights increased significantly in both treatment groups: mean S.E.M. 5% 1% in the highdose group, 6% 1% in the conventional-dose group. Erythrocyte sedimentation rate, WBC and neutrophil count improved to the same degree in the two treatment groups (Table II) . Pulmonary function tests showed a marked increase in vital capacity and FEV1 expressed as percent of the predicted value for height in both groups (Table II ; P 0.001). Thoracic gas volume and total lung capacity did not change after either treatment. BrasfieldHicks X-ray scores improved significantly after both treatments (P 0.005); there was no significant difference between the two treatments.
Bacteriological results were the same for both treatment doses (Table II) . P. aeruginosa was not recovered from the sputum initially after treatment in just over half of the patients; it always reappeared on follow-up culture 1 month later.
There were no allergic reactions, no significant changes in serum creatinine, venous blood haemoglobin content or platelet count. There was a significant increase in ALT after low-dose therapy (P 0.02) and high-dose therapy (P 0.002). The increase was significantly larger after high-dose therapy (P 0.01). Apart from one patient in the high-dose group with a baseline ALT of 31 IU/L that rose to 55 IU/L, all ALT values after treatment were within the normal range (i.e. 45 IU/L).
The time to readmission to hospital was used as a measure of long-term outcome. After high-dose treatment, the median delay was 6 months (P25-P75 range: 2.7-13.2); after conventional-dose treatment patients were readmitted after a median of 4 months (P25-P75 range: 1.5-10). These differences were not significant.
Discussion
Although it has been repeatedly demonstrated that antibiotics improve patient wellbeing, it is difficult to demonstrate the superiority of one treatment regimen over another in CF. In the present study, we compared two different doses of ceftazidime but found no difference in efficacy. There was close similarity between the improvements seen after each treatment dose and between the present trial and a previous one. 4 This suggests that pulmonary disease is partly due to acute infection and thus that it can be reversed by adequate antibiotic treatment. Part of the lung disease is not due to acute bacterial infection but secondary to other pathogenetic mechanisms 8 and cannot be influenced by antibiotic therapy. In patients with P. aeruginosa lung infection susceptible to the drug used, increasing the drug dose further does not bring an In this study the high dose of ceftazidime (320 mg/kg) was not associated with haematological or renal toxicity. Although liver enzymes did increase, all but one value were still within normal limits. In the patient with raised ALT, the value had returned to baseline by the 1 month follow-up. A small increase in ALT has been reported in previous trials. 9 In the present trial the maximum dose given was 18 g/day.
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In conclusion, in CF patients with chronic P. aeruginosa colonization and signs of increasing pulmonary infection, a conventional dose (150 mg/kg) of ceftazidime is as effective as a very high dose (320 mg/kg/day). The high dose was not associated with significant toxicity. The only parameter that differed significantly between the two doses was ALT: mean SEM increase 2% 1% after conventional dose compared with 8% 2% after high-dose treatment (unpaired t-test; P 0.01).
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